1887

Abstract

Bedaquiline (BDQ) has been proven to be effective in the treatment of multidrug-resistant tuberculosis. We hypothesized that BDQ could be a potential agent to treat nontuberculous mycobacterial (NTM) infection. The objective of this study was to evaluate the in vitro activity of BDQ against rapidly growing mycobacteria by assessing the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) against 18 NTM strains. For MIC determination we performed the resazurin microtitre assay broth dilution, and for the MBC the c.f.u. was determined. BDQ exhibited a strong inhibitory effect against most NTM tested; however, for some NTM strains the MBC was significantly higher than the MIC. A new finding is that Mycobacterium flavescens has a mutation in the gene atpE associated with natural resistance to BDQ. These preliminary promising results demonstrate that BDQ could be potentially useful for the treatment of NTM.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000537
2017-07-28
2019-10-16
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/8/1140.html?itemId=/content/journal/jmm/10.1099/jmm.0.000537&mimeType=html&fmt=ahah

References

  1. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev 2014;27:727–752 [CrossRef][PubMed]
    [Google Scholar]
  2. Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med 2016;37:83–96 [CrossRef][PubMed]
    [Google Scholar]
  3. Sommerstein R, Schreiber PW, Diekema DJ, Edmond MB, Hasse B et al. Mycobacterium chimaera outbreak associated with heater-cooler devices: piecing the puzzle together. Infect Control Hosp Epidemiol 2017;38:103–108 [CrossRef][PubMed]
    [Google Scholar]
  4. Frieden TR, Brudney KF, Harries AD. Global tuberculosis: perspectives, prospects, and priorities. JAMA 2014;312:1393–1394 [CrossRef][PubMed]
    [Google Scholar]
  5. Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M et al. Multidrug-resistant tuberculosis around the world: what progress has been made?. Eur Respir J 2015;45:150–160 [CrossRef][PubMed]
    [Google Scholar]
  6. Ma Z, Lienhardt C, Mcilleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100–2109 [CrossRef][PubMed]
    [Google Scholar]
  7. Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol 2013;8:1071–1080 [CrossRef][PubMed]
    [Google Scholar]
  8. Sotgiu G, Pontali E, Centis R, D'Ambrosio L, Migliori GB. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015;13:305–315 [CrossRef][PubMed]
    [Google Scholar]
  9. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223–227 [CrossRef][PubMed]
    [Google Scholar]
  10. Esteban J, García-Pedrazuela M, Muñoz-Egea MC, Alcaide F. Current treatment of nontuberculous mycobacteriosis: an update. Expert Opin Pharmacother 2012;13:967–986 [CrossRef][PubMed]
    [Google Scholar]
  11. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 2016;45:123–134 [CrossRef][PubMed]
    [Google Scholar]
  12. Rubio M, March F, Garrigó M, Moreno C, Español M et al. Inducible and acquired clarithromycin resistance in the Mycobacterium abscessus complex. PLoS One 2015;10:e0140166 [CrossRef][PubMed]
    [Google Scholar]
  13. Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA et al. Emergence of mmpT5 variants during Bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol 2017;55:574–584 [CrossRef][PubMed]
    [Google Scholar]
  14. Palomino JC, Martin A, Camacho M, Guerra H, Swings J et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:2720–2722 [CrossRef][PubMed]
    [Google Scholar]
  15. Martin A, Camacho M, Portaels F, Palomino JC. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003;47:3616–3619 [CrossRef][PubMed]
    [Google Scholar]
  16. Pérez-Martínez I, Ponce-de-León A, Bobadilla M, Villegas-Sepúlveda N, Pérez-García M et al. A novel identification scheme for genus Mycobacterium, M. tuberculosis complex, and seven mycobacteria species of human clinical impact. Eur J Clin Microbiol Infect Dis 2008;27:451–459 [CrossRef][PubMed]
    [Google Scholar]
  17. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51:4202–4204 [CrossRef][PubMed]
    [Google Scholar]
  18. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010;54:1022–1028 [CrossRef][PubMed]
    [Google Scholar]
  19. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006;50:2853–2856 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000537
Loading
/content/journal/jmm/10.1099/jmm.0.000537
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error